About Oxford Science Enterprises
Oxford Science Enterprises is a venture capital firm founded in 2015. It is primarily based out of Oxford, United Kingdom. As of Oct 2026, Oxford Science Enterprises is an active investor, having invested in 130 companies, with 14 new investments in the last 12 months. It primarily invests in Series A round in United Kingdom based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of OMass Therapeutics Overall, Oxford Science Enterprises portfolio has seen 3 IPOs and 14 acquisitions including key companies like Barinthus Biotherapeutics, Pepgen and Oxford Ionics. A lot of funds co-invest with Oxford Science Enterprises, with names like Oxford University Innovation sharing a substantial percentage of its portfolio. Oxford Science Enterprises has team of 41 people including 16 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Oxford Science Enterprises' List of Top Investments
Oxford Science Enterprises has a portfolio of 130 companies. Their most notable investments are in BehaVR and Orbit Discovery.Their portfolio spans across United Kingdom, United States, Canada and 3 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 27 other sectors, across stages such as Seed, Series A and 2 more. Here is the list of top investments by Oxford Science Enterprises:1. BibliU
Provider of digital learning content and campus store management solutions. The platform offers institutions tools to automate content workflows and improve learning outcomes. It provides digital textbooks, monographs, and courseware. The platform integrates with existing systems to deliver an interactive learning experience. It supports diverse academic needs of students and faculty.
Key facts about BibliU
- Founded Year: 2014
- Location: Greenville (United States)
- Annual Revenue: £50M - £100M as on Oct 31, 2024
- Stage: Series C
- Total Funding till date: $102M
- Employee Count: 201 as on Aug 31, 2026
- Investors: Oxford Science Enterprises, GSP Capital and 28 Others
- Latest Funding Round: Series C, Jun 02, 2026, $*****
- Highlight: Editors' Pick
2. Perspectum
Developer of medical imaging software for analyzing liver disease biomarkers. This technology extracts quantitative data from magnetic resonance imaging to assist in the assessment of metabolic and chronic conditions. The software provides diagnostic information to support clinical decision-making and patient monitoring. These tools facilitate the interpretation of complex imaging data for medical professionals.
Key facts about Perspectum
- Founded Year: 2012
- Location: Oxford (United Kingdom)
- Annual Revenue: £10M - £50M as on Dec 31, 2024
- Stage: Series C
- Total Funding till date: $140M
- Employee Count: 279 as on Sep 30, 2026
- Investors: Health Quest Capital, Oppenheimer and 32 Others
- Latest Funding Round: Grant (prize money), Sep 17, 2025, $*****
- Highlight: Editors' Pick
3. Ultromics
Developer of artificial intelligence software for analyzing cardiac ultrasound images. This technology processes echocardiogram video clips to identify patterns associated with specific heart conditions. The software integrates with existing medical imaging systems to provide automated reports for clinical review. These tools assist in the detection of heart failure and other cardiovascular abnormalities by identifying findings within routine diagnostic scans. The system functions through cloud-based infrastructure to deliver results directly into clinical workflows.
Key facts about Ultromics
- Founded Year: 2017
- Location: Oxford (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2025
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $116M
- Employee Count: 83 as on Sep 30, 2026
- Investors: GT Healthcare Capital Partners, Mayo Clinic Business Accelerator and 23 Others
- Latest Funding Round: Series C, Dec 22, 2025, $*****
- Highlight: Editors' Pick
4. ONI
Biotechnology company specializing in super-resolution microscopy systems. These instruments utilize single molecule localization techniques to visualize biological structures at the nanoscale. The product line includes benchtop microscopes capable of various imaging modalities such as dSTORM, PALM, and DNA-PAINT. These systems support applications in cell biology, microbiology, and nanoparticle characterization. The hardware integrates with cloud-based software platforms designed for data analysis, clustering, and collaborative research. Additionally, the company provides reagents and kits to facilitate sample labeling and preparation for high-precision imaging workflows.
Key facts about ONI
- Founded Year: 2016
- Location: Oxford (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2024
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $113M
- Employee Count: 208 as on Sep 30, 2026
- Investors: GT Healthcare Capital Partners, Artis Ventures and 21 Others
- Latest Funding Round: Series B, Dec 21, 2021, $*****
- Highlight: Editors' Pick
Developer of therapeutics for immunological and orphan diseases. The company's technology platform, called OdyssION, allows them to study protein assemblies and the interactions of targets within their native biological ecosystems with high resolution. The company is advancing a pipeline of small molecule therapeutics primarily for immunological and orphan diseases, using genetic and immune signature stratification to select targets with low translation risk.
Key facts about OMass Therapeutics
- Founded Year: 2016
- Location: Oxford (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2025
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $476M
- Employee Count: 74 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, Janus Henderson Investors and 13 Others
- Latest Funding Round: Series C, Oct 15, 2026, $*****
- Highlight: Editors' Pick
Oxford Science Enterprises' Year-on-Year Investment Trends
Oxford Science Enterprises has invested in 130 companies over the last 11 years, with an average of 8 new investments annually in the last 10 years. In 2025, it made 12 investments, while as of Oct 2026, it has made 20 investments in this year. Its most recent first time investment was in ReEmerge and most recent follow-on round was in OMass Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 11 | 9 | 20 |
2025 | 9 | 3 | 12 |
2024 | 4 | 8 | 12 |
2023 | 11 | 8 | 19 |
2022 | 9 | 10 | 19 |
2021 | 5 | 12 | 17 |
2020 | 11 | 7 | 18 |
2019 | 6 | 0 | 6 |
2018 | 10 | 7 | 17 |
2017 | 3 | 3 | 6 |
Oxford Science Enterprises' Investments by Stage
Oxford Science Enterprises has made 51 investments in Seed stage with an average round size of $4.96M, 31 investments in Series A stage with an average round size of $25.4M, 10 investments in Series B stage with an average round size of $33M and 1 investment in Series C stage with an average round size of $85M.Stage of entry | No. of Investments |
|---|---|
Seed | 51 |
Series A | 31 |
Series B | 10 |
Series C | 1 |
Note: We have considered here, only first round of investments
Oxford Science Enterprises' Investments by Sector
Oxford Science Enterprises has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, HealthTech and Sustainability Tech. Notably, it has invested in 113 Tech companies, 109 Enterprise (B2B) companies, 43 Tech hardware companies and at least 41 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 37 |
Enterprise Applications | 28 |
High Tech | 28 |
HealthTech | 17 |
Sustainability Tech | 12 |
Others | 76 |
Note: We have considered here, only first round of investments
Oxford Science Enterprises' Investments by Geography
Oxford Science Enterprises has made most investments in United Kingdom (77), followed by United States where it has made 9 investments.Country | No. of Investments |
|---|---|
United Kingdom | 77 |
United States | 9 |
Canada | 1 |
Finland | 1 |
Netherlands | 1 |
Note: We have considered here, only first round of investments
Oxford Science Enterprises' recent investments
Oxford Science Enterprises has made 20 investments in 2026 so far. OMass Therapeutics and Salience Labs are the latest among them.Here are the most recent investments by Oxford Science Enterprises:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 15, 2026 | United Kingdom | Series C | 8862 | ||
Oct 12, 2026 | United Kingdom | Series B | 1402 | [+8] | |
Sep 15, 2026 | - | Series A | 9791 | [+4] | |
Sep 09, 2026 | - | Seed | 6191 | ||
Aug 17, 2026 | United Kingdom | Seed | 8404 |
IPOs and Publicly Listed companies in Oxford Science Enterprises' Portfolio
3 of Oxford Science Enterprises' portfolio companies have become public. Pepgen got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2022 at marketcap of $269M and Barinthus Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $579M.Here are Oxford Science Enterprises' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 06, 2022 | Nov 24, 2020 | Series A | 6186 | |
Apr 30, 2021 | May 12, 2016 | Seed | 6424 | |
- | - | - | 2999 |
Acquired companies in Oxford Science Enterprises' Portfolio
14 companies from Oxford Science Enterprises' portfolio have been acquired. The most recent acquisition was Brill Power in Aug 2025 by Palmer Energy Technology for $*****.Here are Oxford Science Enterprises' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 28, 2025 | Feb 17, 2021 | Seed | 8122 | |
Jun 09, 2025 | Jan 09, 2023 | Series A | 7051 | |
Feb 18, 2025 | - | - | 7528 | |
Jul 16, 2024 | Jun 06, 2019 | Series A | 6157 | |
Oct 20, 2022 | Dec 22, 2020 | Series A | 5161 |
Team profile of Oxford Science Enterprises
Oxford Science Enterprises has a team of 41 members including 16 Partners, 4 Venture Partners and 6 Principals located in United Kingdom. Oxford Science Enterprises' team sits on the board of 4 companies.Here is a list of top team members in Oxford Science Enterprises:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | United Kingdom | - | - | |
Partner | London | - | ||
Partner | United Kingdom | - | - | |
Partner | London | - | - | |
Partner | United Kingdom | Mixergy, Oxford Flow and 1 more | - | |
Partner | United Kingdom | - | - | |
Partner | Bristol | - | - | |
Partner | London | - | - | |
Partner | United Kingdom | - | - |
Co-investors of Oxford Science Enterprises
Over the past 11 years, 437 investors have co-invested in Oxford Science Enterprises's portfolio companies. This includes funds and angels.
- Invested before Oxford Science Enterprises: Parkwalk, Europa and 53 others have invested in rounds before Oxford Science Enterprises. There are 8 companies where Parkwalk has invested before Oxford Science Enterprises and 5 companies where Europa has invested before Oxford Science Enterprises.
- Top Co-investors of Oxford Science Enterprises: 179 investors entered a company along with Oxford Science Enterprises. These include investors like Oxford University Innovation (6 companies).
- Invested after Oxford Science Enterprises: A total of 203 investors have invested in Oxford Science Enterprises's portfolio after their investments. Top Investors include Oxford (13 companies), British Business Bank (6 companies) and Oxford University Innovation (6 companies).
Recent News related to Oxford Science Enterprises
•
Salience Labs Raises $125m for Photonics ICsElectronics Weekly•Oct 15, 2026•Cambridge Innovation Capital, Silicon Catalyst, Salience Labs, Intel Capital and 9 others
•
Living Optics Closes Funding Round of £20MinVISION News•Oct 08, 2026•Oxford Science Enterprises, Foresight Group, Octopus Ventures, Braavos and 1 other
•
MCatalysis Raises $5M in Seed FundingFinSMEs•Sep 09, 2026•Oxford Science Enterprises, MCatalysis, Hlenergyventures, Ukri
•
Oxford Spinout Mirae Secures $5.4M to Scale AI Chronic Care PlatformHIT Consultant•Jul 28, 2026•Oxford Science Enterprises
•
Vivid Dx Raises $15M to Combat Drug-Resistant InfectionsPR Newswire•Jul 28, 2026•Vivid Dx, Oxford Science Enterprises, Cedars Sinai
•
Moa Technology Secures £22.2 Million Series C Funding to Advance Novel Herbicide DevelopmentPR Newswire•Jul 23, 2026•Oxford Science Enterprises, Supernova Invest, MoA Technology, GrainInnovate
•
EQT Life Sciences Participates in RQ Bio's USD 115 Million Series A FinancingPR Newswire•Jun 24, 2026•Frazier Life Sciences, EQT, RQ Bio, Forbion and 6 others
•
Oxford Quantum Circuits Secures Record £260m in European Quantum Computing FundingNew Electronics•Jun 03, 2026•Oqc Tech, Oxford Science Enterprises, Chevron, J P Morgan and 1 other
•
Startup harnessing energy from tides raises £4.3mUKTN•May 27, 2026•Creator Fund, Empirical Ventures, Caudal Energy, Zero Carbon Capital and 3 others
•
Oxford-based Caudal Energy lands €4.9 million to develop predictable renewable power from tidal flowEU-Startups•May 27, 2026•Empirical Ventures, Oxford Science Enterprises, Zero Carbon Capital, Creator Fund
